Literature DB >> 8606717

Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1.

S K Stanley1, M A Ostrowski, J S Justement, K Gantt, S Hedayati, M Mannix, K Roche, D J Schwartzentruber, C H Fox, A S Fauci.   

Abstract

BACKGROUND: Activation of the immune system is a normal response to antigenic stimulation, and such activation enhances the replication of human immunodeficiency virus type 1 (HIV-1). We studied the effect of immunization with a common recall antigen on viral expression in HIV-1-infected patients, on the ability to isolate virus, and on the susceptibility to HIV-1 infection of peripheral-blood mononuclear cells (PBMCs) from control subjects not infected with HIV-1.
METHODS: Thirteen HIV-1-infected patients and 10 uninfected adults were given a 0.5-ml booster dose of tetanus toxoid. Studies were performed to evaluate changes in the degree of plasma viremia, proviral burden, the ability to isolate HIV-1, and the susceptibility of PBMCs to acute infection in vitro. Two patients underwent sequential lymph-node biopsies for the assessment of viral burden in these tissues.
RESULTS: All 13 HIV-1-infected patients had transient increase in plasma viremia after immunization, and the proviral burden increased in 11. These changes did not correlate with the base-line CD4+ T-cell counts. The lymph-node tissue also had increases in the proviral burden and viral RNA after immunization. The virus was more easily isolated from PBMCs from nine of the patients after immunization than before immunization. Despite considerable variability in the results, PBMCs from 7 of the 10 normal subjects were more easily infected in vitro with HIV-1 after immunization than before immunization.
CONCLUSIONS: Activation of the immune system by an ongoing antigen-specific immune response to an exogenous stimulus transiently increases the expression of HIV-1 and may enhance the susceptibility of uninfected subjects to HIV-1.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8606717     DOI: 10.1056/NEJM199605093341903

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  60 in total

1.  Antigen-driven CD4+ T cell and HIV-1 dynamics: residual viral replication under highly active antiretroviral therapy.

Authors:  N M Ferguson; F deWolf; A C Ghani; C Fraser; C A Donnelly; P Reiss; J M Lange; S A Danner; G P Garnett; J Goudsmit; R M Anderson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-12-21       Impact factor: 11.205

2.  Naive CD4 T cells inhibit CD28-costimulated R5 HIV replication in memory CD4 T cells.

Authors:  M Mengozzi; M Malipatlolla; S C De Rosa; L A Herzenberg; L A Herzenberg; M Roederer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-18       Impact factor: 11.205

3.  Studies of AIDS vaccination using an ex vivo feline immunodeficiency virus model: protection conferred by a fixed-cell vaccine against cell-free and cell-associated challenge differs in duration and is not easily boosted.

Authors:  D Matteucci; M Pistello; P Mazzetti; S Giannecchini; D Del Mauro; I Lonetti; L Zaccaro; C Pollera; S Specter; M Bendinelli
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir.

Authors:  Tae-Wook Chun; David C Nickle; J Shawn Justement; Danielle Large; Alice Semerjian; Marcel E Curlin; M Angeline O'Shea; Claire W Hallahan; Marybeth Daucher; Douglas J Ward; Susan Moir; James I Mullins; Colin Kovacs; Anthony S Fauci
Journal:  J Clin Invest       Date:  2005-11       Impact factor: 14.808

5.  R5 variants of human immunodeficiency virus type 1 preferentially infect CD62L- CD4+ T cells and are potentially resistant to nucleoside reverse transcriptase inhibitors.

Authors:  Françoise Gondois-Rey; Angelique Biancotto; Marcelo Antonio Fernandez; Lise Bettendroffer; Jana Blazkova; Katerina Trejbalova; Marjorie Pion; Ivan Hirsch
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

6.  T cell responses of HIV-infected children after administration of inactivated or live attenuated influenza vaccines.

Authors:  Adriana Weinberg; Lin-Ye Song; Terence Fenton; Sharon A Nachman; Jennifer S Read; Julie Patterson-Bartlett; Myron J Levin
Journal:  AIDS Res Hum Retroviruses       Date:  2010-01       Impact factor: 2.205

7.  Monocytes modulate enhancement of HIV-1 replication by Mycobacterium tuberculosis.

Authors:  C J De Haas; N M de Vos; M R Visser; H Snippe; J Verhoef
Journal:  Clin Exp Immunol       Date:  1998-02       Impact factor: 4.330

8.  Productive infection of dendritic cells by HIV-1 and their ability to capture virus are mediated through separate pathways.

Authors:  A Blauvelt; H Asada; M W Saville; V Klaus-Kovtun; D J Altman; R Yarchoan; S I Katz
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

9.  Elevated levels of macrophage migration inhibitory factor (MIF) in the plasma of HIV-1-infected patients and in HIV-1-infected cell cultures: a relevant role on viral replication.

Authors:  Eduardo G Regis; Victor Barreto-de-Souza; Mariza G Morgado; Marcelo T Bozza; Lin Leng; Richard Bucala; Dumith C Bou-Habib
Journal:  Virology       Date:  2010-01-20       Impact factor: 3.616

10.  Human immunodeficiency virus type 1 protease inhibitors block toll-like receptor 2 (TLR2)- and TLR4-Induced NF-kappaB activation.

Authors:  Ozlem Equils; Alan Shapiro; Zeynep Madak; Chunren Liu; Daning Lu
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.